Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
about
The evolution of poxvirus vaccinesExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVAPre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverPreclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesNovel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral ProteinsImmediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesModified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cellsPhase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesRole of cell signaling in poxvirus-mediated foreign gene expression in mammalian cellsEnhancing poxvirus vectors vaccine immunogenicity.Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.Generation of Recombinant Vaccinia VirusesAntigenic properties of the HIV envelope on virions in solution.HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding siteA trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.Virus-Like-Vaccines against HIV.Generation of Recombinant Vaccinia Viruses.Generation of Recombinant Vaccinia VirusesDNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination
P2860
Q26995905-74A0A872-604A-4E9A-B908-F4F591BCB754Q28727937-D7EC16CC-EAF2-409C-9CA9-04D8F34237A4Q28740522-BE3D47C0-692E-4B24-A93A-B9439AEC1B26Q30374995-4F30D598-C18B-4E5A-9794-D0F0C329B164Q30375489-A5CD1903-4514-4909-8136-8E5EE8406FDFQ33627613-7385239E-6F2F-4CBF-BC2C-7FB058A0AF24Q33653229-EF1A9BA4-0028-4570-9DE2-F02592C341B6Q33770634-DD97A22B-2E76-40A4-9CF2-BC5E282631E6Q34055541-71201291-8A87-433F-9C35-28C1271242A3Q34605490-0BDC94FB-E267-4FD4-BDA9-A454E92EA688Q34772727-48767031-653F-4A63-97ED-38D1784B33FAQ34952043-8DAFF025-B8A4-4462-9742-70DC71811DA9Q35292450-83D633F0-631B-42AE-91D2-4A7A2C961654Q36978452-189BC2BB-E554-4CEB-B916-B0CB02CE12DBQ37248017-A60CBD0A-B670-4AA5-9D41-91F6BEC11A94Q37346420-F1FBD548-9BF5-409A-8095-44DE32773D6DQ37441748-1BDD399D-FA35-4444-8344-A47436EB87F0Q37547245-BE59C399-12CB-41E7-BE30-27AA192DCB6BQ41918753-24915F12-38EB-4CBE-89B1-19D32AD69C66Q41919287-A7487F4C-5B83-49CB-8DB7-DC8EFA05C9F3Q47296227-28C5255D-AAA5-4F5A-BB06-7F3BF3B4D9B7Q50034030-69CBDDA7-FFD0-464F-A337-F1490F653B77Q53860110-5518C22D-0432-4307-BDE2-FB7DEF39B127Q56972744-C3F3D5E6-2B1F-4A30-8B0F-355424FA1550Q58711069-A2330A89-D6B6-45EC-892A-2FB8F5B05930
P2860
Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@ast
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@en
type
label
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@ast
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@en
prefLabel
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@ast
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@en
P2093
P2860
P1433
P1476
Correlation of immunogenicitie ...... nia virus Ankara HIV vaccines.
@en
P2093
Dev Chandran
Harriet L Robinson
Jennifer Vogt
Jinyan Liu
Leigh Anne Eller
Linda S Wyatt
Patricia L Earl
P2860
P304
P356
10.1016/J.VACCINE.2007.11.036
P407
P50
P577
2007-12-03T00:00:00Z